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INTRODUCTION
▪ Tissue plasminogen activator (tPA) was first approved by the 
Food and Drug Administration (FDA) in 1996 for the treatment of 
acute ischemic stroke.2
▪ tPA is given intravenously (IV) and dosed based on the patient’s 
weight. Studies have shown that tPA is dosed incorrectly in 29% 
of cases due to weight discrepancies.1 Inaccurately dosing tPA is 
associated with negative outcomes, including bleeding.1
▪ Gwinnett Medical Center (GMC) is a 500-bed community hospital 
and an advanced primary stroke center. tPA is dosed using a 
chart with pre-determined total dose, bolus dose and infusion 
doses based on the patient’s weight, which is rounded to 2-3 kg 
intervals. 
▪ Door-to-needle (DTN) time is defined as the time between the 
arrival to the emergency department (ED) and the administration 
of the tPA bolus dose; the national goal DTN time is less than 60 
minutes. Studies have shown a statistically significant decrease in 
mortality for every 15-minute reduction in time to tPA 
administration.4
▪ To meet core measures, 50% of patients must receive tPA 
within 60 minutes. However, nationwide only 30% of patients 
receive tPA within this window.3
▪ At GMC, an ED pharmacist is only present during the hours of 
1:30 pm to midnight seven days a week and has been a part of 
the ED stroke team since August 2015.
▪ Primary endpoint is to compare stroke patients who received tPA 
with a DTN time <60 minutes with and without a pharmacist 
present. 
▪ Secondary endpoint is the accuracy of the patient’s weight used 
to calculate the tPA dose with and without a pharmacist present.
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admission (within 72 hours).
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• This review shows the potential benefits of having a pharmacist 
as a member of the stroke team.  
• The percent of patients with a DTN <60 minutes was higher with 
a pharmacist absent and was likely due to confounding variables 
and a small sample size. Regardless, both groups were above 
the national average and the DTN time was improved by an 
average of 9 minutes when a pharmacist was present.
• tPA was more accurately dosed when the pharmacist was 
present. This is likely due to the pharmacist weighing the patient 
using a scale or ED bed, instead of using the patient’s stated 
weight to dose tPA. 
• In accordance with the American Stroke Association/American 
Heart Association “Target: Stroke” initiative, the pharmacist may 
play a significant role in preparing the tPA ahead of time and 
having it available for rapid access.3
• The future goal at GMC is to have 75% of patients receive tPA 
within 60 minutes, of which half of those patients should have a 
DTN time < 45 minutes.
METHODS
Primary Endpoint
Secondary Endpoint
Patient Demographics
N=50
Average Age 
(years)
Gender
Average Weight (kg)
Male (%) Female (%)
Pharmacist Present 67 44 56 81 (52-118)
Pharmacist Absent 66 48 52 81 (56-141)
P-Value 0.87 0.77   0.99
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P = 0.164
